Trials Near Add Your Location

Sorting 194 trials by

Accepting patients

CARTITUDE-10

A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

Talisman

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 2

Accepting patients

QUINTESSENTIAL-2

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

MagnetisMM-32

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Accepting patients

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

DREAMM-10

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 3

Accepting patients

EXCALIBER - Maintenance

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
  • CELMoD
  • Randomization
  • Post-Autologous Stem Cell Transplant
  • Phase 3

Accepting patients

inMMyCAR

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
  • CAR T Cell
  • BCMA
  • Phase 1
  • Has results

Accepting patients

CA057-003

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
  • CELMoD
  • Phase 1/2
  • Has results

Accepting patients

MagnetisMM-20

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results
47 hidden based on your filters.Show All